TYK Medicines, Inc (HKG:2410)

Market Cap	3.86B -64.8%
Revenue (ttm)	117.25K
Net Income	-306.91M
EPS	-0.85
Shares Out	380.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,718,000
Average Volume	2,253,365
Open	9.81
Previous Close	9.91
Day's Range	9.81 - 10.28
52-Week Range	9.81 - 41.40
Beta	n/a
RSI	34.38
Earnings Date	Mar 30, 2026

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 163
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2410

Financial Performance

Financial numbers in CNY